← Patent-cliff monitor Loss of exclusivity September 2041 latest FDA-listed patent expiry
Company Novartis → See this company's full patent-cliff portfolio Drug detail Brand name PLUVICTO Active ingredient LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN Strength 27mCi/ML Dosage form SOLUTION Route INTRAVENOUS Modality Small molecule FDA approval March 2022 Marketing status RX
Listed patents Patent Expires Type 12208102 September 2041 use U-4593 10398791 March 2036 substance, product 11951190 November 2035 use U-4593 11318121 August 2028 substance, product 10406240 August 2028 substance, product
Regulatory exclusivity Code Expires I-996 July 2029 I-965 March 2028 NCE March 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.